Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib plus ruxolitinib versus placebo plus ruxolitinib for myelofibrosis with suboptimal response to ruxolitinib
MOH_2021-08-26_010032Phase 3Completed
- Sponsor
- Incyte
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelofibrosis (MF) comparing Parsaclisib plus ruxolitinib with Placebo plus ruxolitinib (2 arms). Primary endpoint: Spleen volume at Week 24. Started Aug 2021; status: completed.
02
Drugs
parsaclisibruxolitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on MOH_2021-08-26_010032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-08-26_010032.